| HealthPartners | Gene therapy for dystrophic epidermolysis bullosa | 2025-10-01 |
| HealthPartners | Gene therapy for hemophilia A (Roctavian™) | 2025-10-01 |
| HealthPartners | GnRH agonists for pubertal suppression | 2025-10-01 |
| HealthPartners | Hereditary angioedema (HAE) drug therapy | 2025-10-01 |
| HealthPartners | Hereditary angioedema (HAE) drug therapy – | 2025-10-01 |
| HealthPartners | Medications for risk reduction of primary breast | 2025-10-01 |
| HealthPartners | Mucopolysaccharidoses (MPS) drug therapy | 2025-10-01 |
| HealthPartners | Mucopolysaccharidoses (MPS) drug therapy – | 2025-10-01 |
| HealthPartners | Omadacycline (Nuzyra®) – Minnesota Healthcare | 2025-10-01 |
| HealthPartners | Omidubicel-onlv (Omisirge®) | 2025-10-01 |